Business
Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials
Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch1 of Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials. Glenmark's Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Naropin®2 Injection, 40 mg/20 mL (2 mg/mL), 150 mg/
About this update from Glenmark Pharmaceuticals Limited
[{"type":"text","content":"ELMWOOD PARK, N.J., Oct. 24, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch1 of Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials. Glenmark's Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Naropin®2 Injection, 40 mg/20 mL (2 mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL), of Fresenius Kabi USA, LLC NDA – 020533. Glenmark will begin distribution in November 2025.","length":691,"tagName":"p"},{"type":"image","alt":"PRNE_Glenmark_Logo","displaySize":"","headline":null,"caption":"PRNE_Glenmark_Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":248,"url":"https://media.zenfs.com/en/prnewswire.com/665b8e82087cbb982ffe3ea107634a26"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QQPQSICzWHjx5eGgMRHVrQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQzNztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/665b8e82087cbb982ffe3ea107634a26","width":400,"height":248}}},{"type":"text","content":"According to IQVIA® sales data for the 12-month period ending August 2025, the Naropin® Injection, 40 mg/20 mL (2 mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) market3 achieved annual sales of approximately $20.9 million*.","length":251,"tagName":"p"},{"type":"text","content":"Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, "We are pleased to announce the launch of Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials. This launch represents another important addition to Glenmark's expanding injectable portfolio and reinforces our dedication to bring quality and affordable alternatives to market for patients in need."","length":489,"tagName":"p"},{"type":"text","content":"1Glenmark's Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials is only approved for the indication(s) listed in Glenmark's approved label.","length":228,"tagName":"p"},{"ty...